Spyre Therapeutics, Inc.
SYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636282
In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $9.92B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $12.3M in total
- 6
- 13F holdersQ2 2026, +69 vs. previous quarter
- 265
- 13F valueReported value at the end of Q2 2026
- $8.52B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $0
- No comparable prior period
- Net income, FY2025
- -$155.2M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 11.6M
- Shares sold short
- Change
- −887.9K
- −7.1% vs. previous
- Days to cover
- 12.69
- At average daily volume
Superinvestors holding SYRE, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding SYRE at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Spyre Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2026 (view filing)9:30 PM ET | Oct 1 | 1 day | King-Jones HeidySee Remarks | SSale | −28.9K | $91.03 | −$2.63M | −91.0%2.85K after | 5 lots10b5-1 |
| Oct 2, 2026 (view filing)9:29 PM ET | Oct 1 | 1 day | Turtle CameronChief Executive Officer | SSale | −15.0K | $92.01 | −$1.38M | −2.7%537.5K after | 6 lots10b5-1 |
| Oct 2, 2026 (view filing)9:29 PM ET | Sep 30-Oct 1 | 2 days | Burrows Scott LChief Financial Officer | SSale | −25.0K | $90.47 | −$2.26M | −23.9%79.8K after | 6 lots10b5-1 |
| Sep 3, 2026 (view filing)9:34 PM ET | Sep 1-2 | 2 days | King-Jones HeidySee Remarks | SSale | −28.4K | $87.35 | −$2.48M | −90.9%2.85K after | 5 lots10b5-1 |
| Sep 3, 2026 (view filing)9:33 PM ET | Sep 1-2 | 2 days | Burrows Scott LChief Financial Officer | SSale | −25.7K | $88.75 | −$2.28M | −24.4%79.8K after | 5 lots10b5-1 |
| Sep 3, 2026 (view filing)9:33 PM ET | Sep 1 | 2 days | Turtle CameronChief Executive Officer | SSale | −15.0K | $87.29 | −$1.31M | −2.6%552.5K after | 4 lots10b5-1 |
| Aug 10, 2026 (view filing)9:31 PM ET | Aug 7 | 3 days | Albers Jeffrey W.Director | SSale | −5.00K | $104.47 | −$522.4K | −100.0%0 after | 10b5-1 |
| Aug 10, 2026 (view filing)9:31 PM ET | Aug 7 | 3 days | Albers Jeffrey W.Director | SSale | −18.0K | $104.55 | −$1.88M | −65.8%9.36K after | 2 lots10b5-1 |
| Aug 5, 2026 (view filing)9:32 PM ET | Aug 3 | 2 days | Burrows Scott LChief Financial Officer | SSale | −7.50K | $95.57 | −$716.8K | −7.1%98.0K after | 3 lots10b5-1 |
| Aug 5, 2026 (view filing)9:31 PM ET | Aug 3 | 2 days | Turtle CameronChief Executive Officer | SSale | −15.0K | $95.51 | −$1.43M | −2.6%567.5K after | 5 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 265 holdersThe largest institutional positions in Spyre Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 13,026,187 | $1.16B | 0.05% | +1,245,163+10.6% | Added |
| BlackRock, Inc. | 6,506,605 | $577.7M | 0.01% | +985,384+17.8% | Added |
| Perceptive Advisors LLC | 4,319,496 | $383.5M | 5.95% | +536,271+14.2% | Added |
| RTW Investments, LP | 4,251,996 | $377.5M | 3.22% | +80,000+1.9% | Added |
| Paradigm Biocapital Advisors LP | 3,840,778 | $341.0M | 6.38% | +1,883,512+96.2% | Added |
| Vanguard Capital Management LLC | 3,448,681 | $306.2M | 0.01% | +391,280+12.8% | Added |
| State Street Corp | 3,057,416 | $271.4M | 0.01% | +450,385+17.3% | Added |
| VR Adviser, LLC | 2,985,448 | $265.0M | 8.04% | −700,000−19.0% | Reduced |
| Price T Rowe Associates Inc | 2,960,855 | $262.9M | 0.03% | +1,362,125+85.2% | Added |
| Driehaus Capital Management LLC | 2,799,166 | $248.5M | 1.44% | +8,381+0.3% | Added |
Holders of 5% or more of SYRE
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Spyre Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 13D/A | 9.99%10.2M shares | 0.00 ppfrom 9.99% | Jun 30, 20239 filings | Oct 9, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.60%3.96M shares | – | Oct 22, 20243 filings | Jul 16, 2025 | SEC |
| Paradigm Biocapital Advisors LP | 13G | 5.10%4.46M shares | New | Oct 1, 20261 filing | Oct 1, 2026 | SEC |